Overview

Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the treatment effect of panitumumab plus FOLFIRI compared to FOLFIRI alone as second line therapy for metastatic colorectal cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Treatments:
Antibodies, Monoclonal
Irinotecan
Panitumumab